{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:40:03Z","timestamp":1788183603842,"version":"build-2803163510"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>The global prevalence of atrial fibrillation is rapidly increasing, in large part due to the aging of the population. Atrial fibrillation is known to increase the risk of thromboembolic stroke by 5 times, but it has been evident for decades that well-managed anticoagulation therapy can greatly attenuate this risk. Despite advances in pharmacology (such as the shift from vitamin K antagonists to direct oral anticoagulants) that have increased the safety and convenience of chronic oral anticoagulation in atrial fibrillation, a preponderance of recent observational data indicates that protection from stroke is poorly achieved on a population basis. This outcomes deficit is multifactorial in origin, stemming from a combination of underprescribing of anticoagulants (often as a result of bleeding concerns by prescribers), limitations of the drugs themselves (drug\u2013drug interactions, bioaccumulation in renal insufficiency, short half-lives that result in lapses in therapeutic effect, etc), and suboptimal patient adherence that results from lack of understanding\/education, polypharmacy, fear of bleeding, forgetfulness, and socioeconomic barriers, among other obstacles. Often this adherence is not reported to treating clinicians, further subverting efforts to optimize care. A multidisciplinary, interprofessional panel of clinicians met during the 2023 International Society of Thrombosis and Haemostasis Congress to discuss these gaps in therapy, how they can be more readily recognized, and the potential for factor XI-directed anticoagulants to improve the safety and efficacy of stroke prevention. A full appreciation of this potential requires a reevaluation of traditional teaching about the \u201ccoagulation cascade\u201d and decoupling the processes that result in (physiologic) hemostasis and (pathologic) thrombosis. The panel discussion is summarized and presented here.<\/jats:p>","DOI":"10.1097\/hpc.0000000000000351","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:01:53Z","timestamp":1718395313000},"page":"47-57","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics"],"prefix":"10.1097","volume":"23","author":[{"given":"Shaun G.","family":"Goodman","sequence":"first","affiliation":[{"name":"From the Division of Cardiology, St Michael\u2019s Hospital, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada"},{"name":"Canadian VIGOUR Centre and Division of Cardiology, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Center, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles V.","family":"Pollack","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kori","family":"Leblanc","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Kwaku","sequence":"additional","affiliation":[{"name":"Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CPC Clinical Research, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellanie","family":"True Hills","sequence":"additional","affiliation":[{"name":"StopAfib.org, American Foundation for Women\u2019s Health, Decatur, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campello","sequence":"additional","affiliation":[{"name":"Department of Medicine, General Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Padova University Hospital, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Hematology Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"R1-20250506","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-0028-1086123","article-title":"Guidelines for the management of anticoagulant therapy.","volume":"2","author":"Gurewich","year":"1976","journal-title":"Semin Thromb Hemost"},{"key":"R2-20250506","doi-asserted-by":"crossref","first-page":"e034778","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies.","volume":"10","author":"Salmasi","year":"2020","journal-title":"BMJ Open"},{"key":"R3-20250506","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation.","volume":"11","author":"Rahman","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"R5-20250506","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060.","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur Heart J"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/europace\/euz141","article-title":"Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI project.","volume":"21","author":"Di Carlo","year":"2019","journal-title":"EP Europace"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ahj.2018.10.004","article-title":"Stroke prevention in atrial fibrillation: closing the gap.","volume":"210","author":"Pokorney","year":"2019","journal-title":"Am Heart J"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the management of atrial fibrillation.","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"R11-20250506","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants.","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"R12-20250506","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/bcp.14362","article-title":"Major bleeding risk associated with oral anticoagulant in real clinical practice. a multicentre 3-year period population-based prospective cohort study.","volume":"86","author":"Bouget","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20250506","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R14-20250506","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.rpth.2023.100655","article-title":"OC 21.4 patient-relevant bleeding events among patients taking anticoagulant medication.","volume":"7","author":"Yi","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"R15-20250506","doi-asserted-by":"crossref","first-page":"e006391","DOI":"10.1161\/JAHA.117.006391","article-title":"Therapeutic strategies following major, clinically relevant nonmajor, and nuisance bleeding in atrial fibrillation: findings from ORBIT-AF.","volume":"7","author":"O\u2019Brien","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R16-20250506","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bmj.38698.709572.55","article-title":"Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.","volume":"332","author":"Choudhry","year":"2006","journal-title":"BMJ"},{"key":"R17-20250506","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry.","volume":"1","author":"Hsu","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R19-20250506","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"R20-20250506","doi-asserted-by":"crossref","first-page":"e239638","DOI":"10.1001\/jamanetworkopen.2023.9638","article-title":"Patients and their physician\u2019s perspectives about oral anticoagulation in patients with atrial fibrillation not receiving an anticoagulant.","volume":"6","author":"Cannon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R21-20250506","first-page":"A14202","article-title":"Abstract 14202: the Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation (BOAT-AF) Study: a prospective, multicenter study evaluating perspectives on use of oral anticoagulation using a patient survey and clinical review by the treating physician among patients not currently treated with oral anticoagulation.","volume":"138","author":"Cannon","year":"2018","journal-title":"Circulation"},{"key":"R22-20250506","doi-asserted-by":"crossref","first-page":"e2242964","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020.","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R23-20250506","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cjca.2021.09.021","article-title":"The introduction of direct oral anticoagulants has not resolved treatment gaps for frail patients with nonvalvular atrial fibrillation.","volume":"38","author":"Orlandi","year":"2022","journal-title":"Can J Cardiol"},{"key":"R24-20250506","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/CIRCULATIONAHA.115.018549","article-title":"Stroke prevention in atrial fibrillation in patients with chronic kidney disease.","volume":"133","author":"Qamar","year":"2016","journal-title":"Circulation"},{"key":"R25-20250506","doi-asserted-by":"crossref","first-page":"e008928","DOI":"10.1161\/JAHA.118.008928","article-title":"Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from ORBIT-AF.","volume":"7","author":"Washam","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R26-20250506","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease.","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"R27-20250506","doi-asserted-by":"crossref","first-page":"e007230","DOI":"10.1161\/CIRCOUTCOMES.120.007230","article-title":"Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation.","volume":"14","author":"Jackevicius","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R28-20250506","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Europace"},{"key":"R29-20250506","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/ehjqcco\/qcab002","article-title":"Concurrent use of P-glycoprotein or cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation.","volume":"8","author":"Sandhu","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R31-20250506","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2016.1841","article-title":"Appropriate apixaban dosing: prescribers take note.","volume":"1","author":"Weitz","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R32-20250506","doi-asserted-by":"crossref","first-page":"e13625","DOI":"10.1111\/ijcp.13625","article-title":"Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: insights from the Optimising Pharmacotherapy in the Management Approach to Lowering Risk in Atrial Fibrillation (OPTIMAL AF) Programme.","volume":"74","author":"Leblanc","year":"2020","journal-title":"Int J Clin Pract"},{"key":"R33-20250506","doi-asserted-by":"crossref","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study.","volume":"9","author":"Sanghai","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R34-20250506","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","article-title":"Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation.","volume":"132","author":"Arbel","year":"2019","journal-title":"Am J Med"},{"key":"R35-20250506","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.","volume":"69","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250506","first-page":"101096","article-title":"Barriers to stroke prevention in atrial fibrillation: insights from the global anticoagulation roundtable.","volume":"42","author":"Barnes","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R37-20250506","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1160\/TH09-11-0799","article-title":"Platelet function testing and risk of bleeding complications.","volume":"103","author":"Ferreiro","year":"2010","journal-title":"Thromb Haemost"},{"key":"R38-20250506","doi-asserted-by":"crossref","first-page":"684638","DOI":"10.3389\/fphar.2021.684638","article-title":"Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice.","volume":"12","author":"Roberti","year":"2021","journal-title":"Front Pharmacol"},{"key":"R39-20250506","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants.","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"R40-20250506","first-page":"100203","article-title":"Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation.","volume":"22","author":"Ido","year":"2022","journal-title":"Am Heart J Plus"},{"key":"R41-20250506","doi-asserted-by":"crossref","first-page":"e005969","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis.","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R42-20250506","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamainternmed.2015.8581","article-title":"Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011.","volume":"176","author":"Qato","year":"2016","journal-title":"JAMA Intern Med"},{"key":"R44-20250506","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2016.11.008","article-title":"Multimorbidity and the risk of hospitalization and death in atrial fibrillation: a population-based study.","volume":"185","author":"Chamberlain","year":"2017","journal-title":"Am Heart J"},{"key":"R45-20250506","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11886-018-0975-x","article-title":"Addressing multimorbidity and polypharmacy in individuals with atrial fibrillation.","volume":"20","author":"Shaikh","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"R47-20250506","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","article-title":"An update on the clinical consequences of polypharmacy in older adults: a narrative review.","volume":"17","author":"Wastesson","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"E50","key":"R48-20250506","first-page":"1","article-title":"Polypharmacy and health-related quality of life\/psychological distress among patients with chronic disease.","volume":"19","author":"Van Wilder","year":"2022","journal-title":"Prev Chronic Dis"},{"key":"R49-20250506","doi-asserted-by":"crossref","first-page":"e016651","DOI":"10.1161\/JAHA.120.016651","article-title":"Clinically meaningful change in quality of life and associated factors among older patients with atrial fibrillation.","volume":"9","author":"Abu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R50-20250506","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"R51-20250506","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy.","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch Intern Med"},{"key":"R52-20250506","doi-asserted-by":"crossref","first-page":"i2868","DOI":"10.1136\/bmj.i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.","volume":"353","author":"Focks","year":"2016","journal-title":"BMJ"},{"key":"R53-20250506","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","article-title":"The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register.","volume":"30","author":"Johnell","year":"2007","journal-title":"Drug Saf"},{"key":"R54-20250506","doi-asserted-by":"crossref","first-page":"22403","DOI":"10.1038\/s41598-021-01786-2","article-title":"Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants.","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"R55-20250506","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjms.2016.01.010","article-title":"Medication adherence: truth and consequences.","volume":"351","author":"Brown","year":"2016","journal-title":"Am J Med Sci"},{"key":"R56-20250506","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/ajh\/hpab046","article-title":"Medication adherence: expanding the conceptual framework.","volume":"34","author":"Krousel-Wood","year":"2021","journal-title":"Am J Hypertens"},{"key":"R57-20250506","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/PPA.S148697","article-title":"Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy.","volume":"12","author":"Stephenson","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"R58-20250506","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease.","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"R59-20250506","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3399\/bjgp16X683557","article-title":"Stroke prevention in atrial fibrillation: we can do better.","volume":"66","author":"Kearney","year":"2016","journal-title":"Br J Gen Pract"},{"key":"R60-20250506","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2021.03.024","article-title":"Cardiovascular outcomes according to polypharmacy and drug adherence in patients with atrial fibrillation on long-term anticoagulation (from the RE-LY Trial).","volume":"149","author":"Millenaar","year":"2021","journal-title":"Am J Cardiol"},{"key":"R61-20250506","first-page":"430","article-title":"Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy.","volume":"24","author":"Deshpande","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"R62-20250506","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.jacadv.2022.100175","article-title":"Reasons for nonadherence to the direct oral anticoagulant apixaban.","volume":"2","author":"Tarn","year":"2023","journal-title":"JACC Adv"},{"key":"R63-20250506","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1538-7836.2010.04031.x","article-title":"Coagulation factor XI as a novel target for antithrombotic treatment.","volume":"8","author":"L\u00f6wenberg","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R64-20250506","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","article-title":"Factor XI deficiency in humans.","volume":"7","author":"Seligsohn","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R65-20250506","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI.","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"key":"R66-20250506","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events.","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"R67-20250506","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis.","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"R68-20250506","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","article-title":"Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.","volume":"4","author":"Wang","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R69-20250506","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R70-20250506","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jth.13766","article-title":"Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein.","volume":"15","author":"Ay","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R71-20250506","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.thromres.2014.03.003","article-title":"A mouse bleeding model to study oral anticoagulants.","volume":"133","author":"Monroe","year":"2014","journal-title":"Thromb Res"},{"key":"R73-20250506","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of tissue factor in hemostasis, thrombosis, and vascular development.","volume":"24","author":"Mackman","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R74-20250506","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week.","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R75-20250506","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week.","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R76-20250506","doi-asserted-by":"crossref","first-page":"903029","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence.","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R77-20250506","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41598-017-02055-x","article-title":"Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.","volume":"7","author":"Donkor","year":"2017","journal-title":"Sci Rep"},{"key":"R78-20250506","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa.","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"R79-20250506","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/FJC.0000000000000921","article-title":"Osocimab: a novel agent in preventing venous thromboembolism.","volume":"76","author":"Beavers","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"R80-20250506","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"R81-20250506","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy.","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"R82-20250506","first-page":"e282","article-title":"Abstract 24578. Late-breaking science abstracts and featured science abstracts from the American Heart Association\u2019s Scientific Sessions 2023 and late-breaking abstracts in resuscitation science from the Resuscitation Science Symposium 2023.","volume":"148","author":"Ruff","year":"2023","journal-title":"Circulation"},{"key":"R83-20250506","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"R84-20250506","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism.","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:02:19Z","timestamp":1746558139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000351","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}